These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15742410)

  • 1. Immune response to an indigenously developed r-hepatitis B vaccine in mixed population: study of an accelerated vaccination schedule.
    Chowdhury A; Santra A; Habibullah CM; Khan AA; Karunakaramaiah J; Kishore TS; Raju AV; Lahiri S
    World J Gastroenterol; 2005 Feb; 11(7):1037-9. PubMed ID: 15742410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.
    Hussain Z; Ali SS; Husain SA; Raish M; Sharma DR; Kar P
    World J Gastroenterol; 2005 Dec; 11(45):7165-8. PubMed ID: 16437665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid immunization effects of a new type of 60 μg hepatitis B vaccine compared with traditional 20 μg hepatitis B vaccines in adults.
    Wang H; Cai B; Rao D; Liu M; Li Y; Liang X; Cui F; Zhang G; Wang F; Pang X; Nie L; Qiu Q; Wu J; Li L; Huang F; Zhang W
    Hum Vaccin Immunother; 2016 Nov; 12(11):2921-2926. PubMed ID: 27648684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.
    Martins RM; Bensabath G; Arraes LC; Oliveira Mde L; Miguel JC; Barbosa GG; Camacho LA
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):865-71. PubMed ID: 15761604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination.
    Baldy JL; de Lima GZ; Morimoto HK; Reiche EM; Matsuo T; de Mattos ED; Sudan LC
    Rev Inst Med Trop Sao Paulo; 2004; 46(2):103-7. PubMed ID: 15141282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
    González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
    Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal vaccination program for healthy adults in China.
    Yao J; Qiu Y; Chen Y; Jiang Z; Shen L; Shan H; Dai X; Li Q; Liu Y; Ren W; Ren J
    Hum Vaccin Immunother; 2015; 11(10):2389-94. PubMed ID: 26158622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.
    Van Herck K; Van Damme P; Collard F; Thoelen S
    Scand J Gastroenterol; 1999 Dec; 34(12):1236-40. PubMed ID: 10636072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
    Vesikari T; Martin JC; Liss CL; Liska V; Schödel FP; Bhuyan PK
    Pediatr Infect Dis J; 2011 Jul; 30(7):e109-13. PubMed ID: 21552183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.
    Leroux-Roels G; Abraham B; Fourneau M; De Clercq N; Safary A
    Vaccine; 2000 Nov; 19(7-8):937-42. PubMed ID: 11115719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
    Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
    Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a recombinant DNA hepatitis B vaccine in a vaccinated Nigerian population.
    Adoga MP; Pennap G; Akande BO; Mairiga JP; Pechulano S; Agwale SM
    J Infect Dev Ctries; 2010 Nov; 4(11):740-4. PubMed ID: 21252452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
    Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
    Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a hepatitis B vaccination schedule with two cycles of four double doses of conventional vaccine and four doses of adjuvanted vaccine in chronic kidney disease patients evaluated for renal transplantation.
    García-Agudo R; Aoufi Rabih S; Araque Torres P; Dolores Fraga Fuentes M; Carlos Valenzuela Gámez J; Mancha Ramos J; María Tenías Burillo J
    Transplant Proc; 2012 Nov; 44(9):2532-4. PubMed ID: 23146445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.